316 related articles for article (PubMed ID: 33716791)
21. CYP epoxygenase derived EETs: from cardiovascular protection to human cancer therapy.
Chen C; Wang DW
Curr Top Med Chem; 2013; 13(12):1454-69. PubMed ID: 23688135
[TBL] [Abstract][Full Text] [Related]
22. Cardiac and vascular KATP channels in rats are activated by endogenous epoxyeicosatrienoic acids through different mechanisms.
Lu T; Ye D; Wang X; Seubert JM; Graves JP; Bradbury JA; Zeldin DC; Lee HC
J Physiol; 2006 Sep; 575(Pt 2):627-44. PubMed ID: 16793897
[TBL] [Abstract][Full Text] [Related]
23. CYP2J2 metabolites, epoxyeicosatrienoic acids, attenuate Ang II-induced cardiac fibrotic response by targeting Gα
He Z; Yang Y; Wen Z; Chen C; Xu X; Zhu Y; Wang Y; Wang DW
J Lipid Res; 2017 Jul; 58(7):1338-1353. PubMed ID: 28554983
[TBL] [Abstract][Full Text] [Related]
24. Endothelium-specific CYP2J2 overexpression improves cardiac dysfunction by promoting angiogenesis via Jagged1/Notch1 signaling.
Zhao Q; Huang J; Wang D; Chen L; Sun D; Zhao C
J Mol Cell Cardiol; 2018 Oct; 123():118-127. PubMed ID: 30219518
[TBL] [Abstract][Full Text] [Related]
25. Cyclooxygenase-derived proangiogenic metabolites of epoxyeicosatrienoic acids.
Rand AA; Barnych B; Morisseau C; Cajka T; Lee KSS; Panigrahy D; Hammock BD
Proc Natl Acad Sci U S A; 2017 Apr; 114(17):4370-4375. PubMed ID: 28396419
[TBL] [Abstract][Full Text] [Related]
26. CYP2J2-Derived EETs Attenuated Angiotensin II-Induced Adventitial Remodeling via Reduced Inflammatory Response.
Zhou C; Huang J; Chen J; Lai J; Zhu F; Xu X; Wang DW
Cell Physiol Biochem; 2016; 39(2):721-39. PubMed ID: 27459385
[TBL] [Abstract][Full Text] [Related]
27. CYP2J2
Tao P; Jiang Y; Wang H; Gao G
Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2021 Sept 28; 46(9):932-941. PubMed ID: 34707002
[TBL] [Abstract][Full Text] [Related]
28. EETs/sEH in diabetes and obesity-induced cardiovascular diseases.
Huang H; Weng J; Wang MH
Prostaglandins Other Lipid Mediat; 2016 Sep; 125():80-9. PubMed ID: 27184755
[TBL] [Abstract][Full Text] [Related]
29. Enzymatic and free radical formation of cis- and trans- epoxyeicosatrienoic acids in vitro and in vivo.
Aliwarga T; Raccor BS; Lemaitre RN; Sotoodehnia N; Gharib SA; Xu L; Totah RA
Free Radic Biol Med; 2017 Nov; 112():131-140. PubMed ID: 28734877
[TBL] [Abstract][Full Text] [Related]
30. Epoxyeicosatrienoic acid analog EET-B attenuates post-myocardial infarction remodeling in spontaneously hypertensive rats.
Neckář J; Hye Khan MA; Gross GJ; Cyprová M; Hrdlička J; Kvasilová A; Falck JR; Campbell WB; Sedláková L; Škutová Š; Olejníčková V; Gregorovičová M; Sedmera D; Kolář F; Imig JD
Clin Sci (Lond); 2019 Apr; 133(8):939-951. PubMed ID: 30979784
[TBL] [Abstract][Full Text] [Related]
31. Epoxyeicosatrienoic acid prevents maladaptive remodeling in pressure overload by targeting calcineurin/NFAT and Smad-7.
Li X; Chu G; Zhu F; Zheng Z; Wang X; Zhang G; Wang F
Exp Cell Res; 2020 Jan; 386(1):111716. PubMed ID: 31734152
[TBL] [Abstract][Full Text] [Related]
32. Early Changes in Cytochrome P450s and Their Associated Arachidonic Acid Metabolites Play a Crucial Role in the Initiation of Cardiac Hypertrophy Induced by Isoproterenol.
Althurwi HN; Maayah ZH; Elshenawy OH; El-Kadi AO
Drug Metab Dispos; 2015 Aug; 43(8):1254-66. PubMed ID: 26033621
[TBL] [Abstract][Full Text] [Related]
33. Pharmacological inhibition of the soluble epoxide hydrolase-from mouse to man.
Revermann M
Curr Opin Pharmacol; 2010 Apr; 10(2):173-8. PubMed ID: 20079692
[TBL] [Abstract][Full Text] [Related]
34. Role of cytochrome P450-mediated arachidonic acid metabolites in the pathogenesis of cardiac hypertrophy.
Alsaad AM; Zordoky BN; Tse MM; El-Kadi AO
Drug Metab Rev; 2013 May; 45(2):173-95. PubMed ID: 23600686
[TBL] [Abstract][Full Text] [Related]
35. Epoxyeicosatrienoic acids (EETs) form adducts with DNA in vitro.
Funk DJ; Sorg BL; Kopka K; Schmeiser HH
Prostaglandins Other Lipid Mediat; 2016 Mar; 123():63-7. PubMed ID: 27166927
[TBL] [Abstract][Full Text] [Related]
36. Reno-protective mechanisms of epoxyeicosatrienoic acids in cardiovascular disease.
Elmarakby AA
Am J Physiol Regul Integr Comp Physiol; 2012 Feb; 302(3):R321-30. PubMed ID: 22116511
[TBL] [Abstract][Full Text] [Related]
37. Increased epoxyeicosatrienoic acids may be part of a protective mechanism in human ulcerative colitis, with increased CYP2J2 and reduced soluble epoxide hydrolase expression.
Qiu YE; Qin J; Luo Y; Qin SL; Mu YF; Cun R; Jiang HL; Chen JJ; Yu MH; Zhong M
Prostaglandins Other Lipid Mediat; 2018 May; 136():9-14. PubMed ID: 29580941
[TBL] [Abstract][Full Text] [Related]
38. Mechanisms by which epoxyeicosatrienoic acids (EETs) elicit cardioprotection in rat hearts.
Gross GJ; Hsu A; Falck JR; Nithipatikom K
J Mol Cell Cardiol; 2007 Mar; 42(3):687-91. PubMed ID: 17217955
[TBL] [Abstract][Full Text] [Related]
39. 14,15-epoxyeicosatrienoic Acid suppresses cigarette smoke extract-induced apoptosis in lung epithelial cells by inhibiting endoplasmic reticulum stress.
Yu G; Zeng X; Wang H; Hou Q; Tan C; Xu Q; Wang H
Cell Physiol Biochem; 2015; 36(2):474-86. PubMed ID: 25968975
[TBL] [Abstract][Full Text] [Related]
40. Prospective for cytochrome P450 epoxygenase cardiovascular and renal therapeutics.
Imig JD
Pharmacol Ther; 2018 Dec; 192():1-19. PubMed ID: 29964123
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
